Lostam BioPharmaceuticals Ltd.

www.lostam-biopharma.com

High-Tech Company

Ceased to Operate Q3/2016

Graduated from: NGT

TECH VERTICALS

Biotechnology, Life Sciences, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2009
Number of Employees	3
Reg. Number:	abCDe

DESCRIPTION

Lostam is developing a novel class of protein therapeutics (“biologics”) aimed to prevent and treat lethal Gram-negative bacterial infections associated primarily within the hospital setting.

TECHNOLOGY

The company uses naturally occurring and validated bacterial targets to generate mAbs, which are then screened in biological activity assays to identify lead mAb candidates. Thereafter, chimeric and humanized mAbs are created using molecular biological techniques as well as novel heterodimeric mAbs. Such therapeutic mAbs are thereafter screened in-vitro and taken for in-vivo feasibility studies using clinically-relevant animal models of infection with end-points including X-ray diagnosis and CT imaging.

Products and Phases

Product	Phase
N/A	Phase III
Lostam BioPharmaceuticals has a panel of six different, chimeric or fully human mAb therapeutic candidates termed LST-003, LST-004, LST-005, LST-006, LST-008 and LST-009. These biologics are currently being screened at the pre-clinical level using a battery of in-vitro assays and a clinically relevant animal model of PA-induced pneumonia. By Q4 2010, the company is confident to identify lead candidate(s) for further development.

	TARGET MARKETS
	Hospitals, Clinics

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Nazareth, Israel

Address	Industrial Area
POB	2252
City	Nazareth
Country	Israel
Zip	1612102

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Lewis Neville	Founder	Zolex (CSO)

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Seed

Oct. 01, 2009

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Oct. 01, 2009

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe	$0.4m

Last Updated:	abCDe
IVC Number:	abCDe